Related references
Note: Only part of the references are listed.Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
A. Strangfeld et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
Roy Fleischmann et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
Julie C. Fitzgerald et al.
CRITICAL CARE MEDICINE (2017)
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
Tsutomu Takeuchi et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis
Cem Gabay et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Ectopic lymphoid follicles: inducible centres for generating antigen-specific immune responses within tissues
Gareth W. Jones et al.
IMMUNOLOGY (2016)
Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial
Tsutomu Takeuchi et al.
MODERN RHEUMATOLOGY (2016)
Baricitinib for the treatment of rheumatoid arthritis
Satoshi Kubo et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2016)
Immunotherapeutic implications of IL-6 blockade for cytokine storm
Toshio Tanaka et al.
IMMUNOTHERAPY (2016)
Arid5a regulates naive CD4+ T cell fate through selective stabilization of Stat3 mRNA
Kazuya Masuda et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial
Johannes W. J. Bijlsma et al.
LANCET (2016)
Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
Peter M. Villiger et al.
LANCET (2016)
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
Dinesh Khanna et al.
LANCET (2016)
Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis: A multi-center, prospective cohort study by the Michinoku Tocilizumab Study Group
Yasuhiko Hirabayashi et al.
MODERN RHEUMATOLOGY (2016)
Rheumatoid arthritis: current and future trends
Kritika Chaudhari et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Family history of rheumatoid arthritis: an old concept with new developments
Thomas Frisell et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
Arid5a exacerbates IFN-γ-mediated septic shock by stabilizing T-bet mRNA
Mohammad Mahabub-Uz Zaman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Histone deacetylase 3 supports endochondral bone formation by controlling cytokine signaling and matrix remodeling
Lomeli R. Carpio et al.
SCIENCE SIGNALING (2016)
RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF SIRUKUMAB, AN ANTI-IL-6 CYTOKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE DISEASE-MODIFYING ANTI-RHEUMATIC DRUG TREATMENT (SIRROUND-D)
T. Takeuchi et al.
VALUE IN HEALTH (2016)
Histone deacetylase 3 supports endochondral bone formation by controlling cytokine signaling and matrix remodeling
Lomeli R. Carpio et al.
SCIENCE SIGNALING (2016)
Dysbiosis Contributes to Arthritis Development via Activation of Autoreactive T Cells in the Intestine
Yuichi Maeda et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica
Lindsay Lally et al.
ARTHRITIS & RHEUMATOLOGY (2016)
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY
Anita Boyapati et al.
ARTHRITIS RESEARCH & THERAPY (2016)
IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future
Go Woon Kim et al.
ARCHIVES OF PHARMACAL RESEARCH (2015)
Regnase-1 and Roquin Regulate a Common Element in Inflammatory mRNAs by Spatiotemporally Distinct Mechanisms
Takashi Mino et al.
CELL (2015)
Interleukin-6: Biology, signaling and strategies of blockade
Fred Schaper et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2015)
Association of interleukin-6 gene polymorphism with coronary artery disease: an updated systematic review and cumulative meta-analysis
Haifeng Hou et al.
INFLAMMATION RESEARCH (2015)
A Novel Small-Molecule Inhibitor Targeting the IL-6 Receptor β Subunit, Glycoprotein 130
Soon-Sun Hong et al.
JOURNAL OF IMMUNOLOGY (2015)
Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan
Kazuhiko Yamamoto et al.
JOURNAL OF RHEUMATOLOGY (2015)
Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6
Qian Zhang et al.
NATURE (2015)
IL-6 as a keystone cytokine in health and disease
Christopher A. Hunter et al.
NATURE IMMUNOLOGY (2015)
Peripheral blood CD4+ CD25+ CD127low regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response
Jun Kikuchi et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Leucine-Rich alpha(2)-Glycoprotein as a Potential Biomarker for Joint Inflammation During Anti-Interleukin-6 Biologic Therapy in Rheumatoid Arthritis
Minoru Fujimoto et al.
ARTHRITIS & RHEUMATOLOGY (2015)
The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Michael E. Weinblatt et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate Results of a Phase III Study
Mark C. Genovese et al.
ARTHRITIS & RHEUMATOLOGY (2015)
An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy
Vijay U. Rao et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Belimumab for Systemic Lupus Erythematosus: A Cochrane Systematic Review and MetaAnalysis
Jasvinder A. Singh et al.
ARTHRITIS & RHEUMATOLOGY (2015)
High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis
Claire Immediato Daien et al.
RHEUMATOLOGY (2015)
A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
Mark C. Genovese et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases
Christoph Garbers et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2014)
Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients with Rheumatoid Arthritis in Japan
Takao Koike et al.
JOURNAL OF RHEUMATOLOGY (2014)
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
Norihiro Nishimoto et al.
Modern Rheumatology (2014)
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
Frits van Rhee et al.
LANCET ONCOLOGY (2014)
Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica A pilot study
Manabu Araki et al.
NEUROLOGY (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy
Toshio Tanaka et al.
SEMINARS IN IMMUNOLOGY (2014)
Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
Atsushi Ogata et al.
ARTHRITIS CARE & RESEARCH (2014)
IL-6 in Inflammation, Immunity, and Disease
Toshio Tanaka et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
AT-Rich-Interactive Domain-Containing Protein 5A Functions as a Negative Regulator of Retinoic Acid Receptor-Related Orphan Nuclear Receptor γt-Induced Th17 Cell Differentiation
Yukari Saito et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Interleukin-6 Receptor Blockade Enhances CD39+Regulatory T Cell Development in Rheumatoid Arthritis and in Experimental Arthritis
A. Thiolat et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Citrullination enhances the pro-inflammatory response to fibrin in rheumatoid arthritis synovial fibroblasts
Olga Sanchez-Pernaute et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
Maxime Dougados et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Circulating plasmablasts/plasmacells as a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis
Priscilla F. Kerkman et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
David T. Teachey et al.
BLOOD (2013)
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Cem Gabay et al.
LANCET (2013)
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
Gerd R. Burmester et al.
LANCET (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo
Kazuya Masuda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Tocilizumab as Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs: Twenty-Four-Week Results of an Open-Label, Clinical Practice Study
Michael E. Weinblatt et al.
ARTHRITIS CARE & RESEARCH (2013)
Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis
Jose U. Scher et al.
ELIFE (2013)
Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice
Vivian P. Bykerk et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Therapeutic Targeting of the Interleukin-6 Receptor
Toshio Tanaka et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 52 (2012)
The origins, function, and regulation of T follicular helper cells
Cindy S. Ma et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald F. van Vollenhoven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab
Atsushi Ogata et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells
Khalid Muhammad et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
In Vivo Effects of the Anti-Interleukin-6 Receptor Inhibitor Tocilizumab on the B Cell Compartment
Petra Roll et al.
ARTHRITIS AND RHEUMATISM (2011)
Tocilizumab Inhibits Structural Joint Damage in Rheumatoid Arthritis Patients With Inadequate Responses to Methotrexate Results From the Double-Blind Treatment Phase of a Randomized Placebo-Controlled Trial of Tocilizumab Safety and Prevention of Structural Joint Damage at One Year
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2011)
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Juergen Scheller et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2011)
IL-6 Trans-Signaling in Formation and Progression of Malignant Ascites in Ovarian Cancer
Chi-Wen Lo et al.
CANCER RESEARCH (2011)
Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model
Tanja Barkhausen et al.
CRITICAL CARE MEDICINE (2011)
IL-6 plays an essential role in neutrophilia under inflammation
Misato Hashizume et al.
CYTOKINE (2011)
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
Simon A. Jones et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
MECHANISMS OF DISEASE The Pathogenesis of Rheumatoid Arthritis
Iain B. McInnes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica
Norio Chihara et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
G. Jones et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Peptidylarginine Deiminase From Porphyromonas gingivalis Citrullinates Human Fibrinogen and α-Enolase Implications for Autoimmunity in Rheumatoid Arthritis
Natalia Wegner et al.
ARTHRITIS AND RHEUMATISM (2010)
Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease
Soken-Nakazawa J. Song et al.
BLOOD (2010)
IL-6: Regulator of Treg/Th17 balance
Akihiro Kimura et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Involvement of Autoimmunity in the Pathogenesis of Aggressive Periodontitis
A. Hendler et al.
JOURNAL OF DENTAL RESEARCH (2010)
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
Tomoyuki Igawa et al.
NATURE BIOTECHNOLOGY (2010)
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Taro Kawai et al.
NATURE IMMUNOLOGY (2010)
Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment
S. Nishida et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer
Sergei Grivennikov et al.
CANCER CELL (2009)
Therapeutic Targeting of IL-6 Trans Signaling Counteracts STAT3 Control of Experimental Inflammatory Arthritis
Mari A. Nowell et al.
JOURNAL OF IMMUNOLOGY (2009)
Heat Shock Protein 96 Is Elevated in Rheumatoid Arthritis and Activates Macrophages Primarily via TLR2 Signaling
Qi-Quan Huang et al.
JOURNAL OF IMMUNOLOGY (2009)
Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay
Kazufumi Matsushita et al.
NATURE (2009)
IL-6/sIL-6R trans-signalling, but not TNF-α induced angiogenesis in a HUVEC and synovial cell co-culture system
Misato Hashizume et al.
RHEUMATOLOGY INTERNATIONAL (2009)
Ectopic Lymphoid Structures Support Ongoing Production of Class-Switched Autoantibodies in Rheumatoid Synovium
Frances Humby et al.
PLOS MEDICINE (2009)
The role of Toll-like receptors in rheumatoid arthritis
Qi-Quan Huang et al.
Current Rheumatology Reports (2009)
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study
Mark C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2008)
Overexpression of Toll-like Receptors 3 and 4 in Synovial Tissue From Patients With Early Rheumatoid Arthritis Toll-like Receptor Expression in Early and Longstanding Arthritis
Caroline Ospelt et al.
ARTHRITIS AND RHEUMATISM (2008)
Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
Norihiro Nishimoto et al.
BLOOD (2008)
IL-6-dependent mucosal protection prevents establishment of a microbial niche for attaching/effacing lesion-forming enteric bacterial pathogens
Sara M. Dann et al.
JOURNAL OF IMMUNOLOGY (2008)
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Josef S. Smolen et al.
LANCET (2008)
Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells
Akihiro Kimura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17
M. Hashizume et al.
RHEUMATOLOGY (2008)
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
Norihiro Nishimoto et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Patterns of cardiovascular risk in rheumatoid arthritis
D. H. Solomon et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Impaired skeletal development in interleukin-6-transgenic mice - A model for the impact of chronic inflammation on the growing skeletal system
Fabrizio De Benedetti et al.
ARTHRITIS AND RHEUMATISM (2006)
NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses
Konstantin D. Taganov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Inflammatory markers and loss of muscle mass (sarcopenia) and strength
Laura A. Schaap et al.
AMERICAN JOURNAL OF MEDICINE (2006)
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
E Bettelli et al.
NATURE (2006)
Differential expression of CD126 and CD130 mediates different STAT-3 phosphorylation in CD4+CD25- and CD25high regulatory t cells
HH Oberg et al.
INTERNATIONAL IMMUNOLOGY (2006)
Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles
SP Linn-Rasker et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
A new model for an etiology of rheumatoid arthritis
L Klareskog et al.
ARTHRITIS AND RHEUMATISM (2006)
Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor
G Skiniotis et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2005)
IL-6-induced skeletal muscle atrophy
F Haddad et al.
JOURNAL OF APPLIED PHYSIOLOGY (2005)
Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IκBζ
M Yamamoto et al.
NATURE (2004)
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody - A multicenter, double-blind, placebo-controlled trial
N Nishimoto et al.
ARTHRITIS AND RHEUMATISM (2004)
IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin
E Nemeth et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: Blockade of arthritis severity by soluble glycoprotein 130
MA Nowell et al.
JOURNAL OF IMMUNOLOGY (2003)
Hexameric structure and assembly of the interleukin-6/IL-6 α-receptor/gp130 complex
MJ Boulanger et al.
SCIENCE (2003)
Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis
H Nakahara et al.
ARTHRITIS AND RHEUMATISM (2003)
IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation
G Kaplanski et al.
TRENDS IN IMMUNOLOGY (2003)
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis
A Kaser et al.
BLOOD (2001)
The IL-6-soluble IL-6Rα autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation:: An experimental model involving thrombin
V Marin et al.
JOURNAL OF IMMUNOLOGY (2001)
IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation
SM Hurst et al.
IMMUNITY (2001)
Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130
SE Nicholson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men
PM Ridker et al.
CIRCULATION (2000)
Share Paper
